Umoja Biopharma Announces Activation of First ENLIGHTen Phase I Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells

Umoja Biopharma, Inc. announced the Seattle Children’s activation of the Phase I ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170, the company’s proprietary small molecule fluorescein tag.